Luke Walker

1.9k citations

39 papers · 489 indexed · h-index 10

Impact in

Otorhinolaryngology top 5%
- Head and Neck Cancer Studies
Oncology top 10%
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies

Papers in ⓘ

Oncology 33
- HER2/EGFR in Cancer Research 21
- Cancer Treatment and Pharmacology 17
Pulmonary and Respiratory Medicine 24
- Advanced Breast Cancer Therapies 12
- Brain Metastases and Treatment 8
- Lung Cancer Treatments and Mutations 6

Co-authors: Diana F. Hausman (8 shared papers)Antonio Jimeno (6 shared papers)Alexander I. Spira (4 shared papers)Daniel W. Bowles (5 shared papers)Charles M. Rudin (4 shared papers)Keisuke Shirai (2 shared papers)Ian D. Schnadig (4 shared papers)Mark D. Kochenderfer (2 shared papers)
Journals: Annals of Oncology (10 papers)Cancer Research (10 papers)Journal of Clinical Oncology (7 papers)Clinical Pharmacokinetics (2 papers)Molecular Cancer Therapeutics (1 paper)
Partner nations: United States Japan Germany

In The Last Decade

Luke Walker

39 papers receiving 489 citations

Peers

Countries citing papers authored by Luke Walker

Since Specialization

Citations

This map shows the geographic impact of Luke Walker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luke Walker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luke Walker more than expected).

Fields of papers citing papers by Luke Walker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luke Walker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luke Walker. The network helps show where Luke Walker may publish in the future.

Co-authors

The 25 scholars most cited alongside Luke Walker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Luke Walker Line = papers co-authored together Luke Walker links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer Annals of Oncology ·Antonio Jimeno, Keisuke Shirai, Minsig Choi, Janessa Laskin, Mark D. Kochenderfer, Alexander I. Spira, Vivian Jean M. Cline-Burkhardt, Eric Winquist, Diana F. Hausman, Luke Walker, Rachel Cohen	2014	82
2	A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer Oral Oncology ·Antonio Jimeno, Julie E. Bauman, Charles Weissman, Douglas R. Adkins, Ian D. Schnadig, Patrice Beauregard, Daniel W. Bowles, Alexander I. Spira, Benjamin Levy, Nagashree Seetharamu, Diana F. Hausman, Luke Walker, Charles M. Rudin, Keisuke Shirai	2015	66
3	A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours British Journal of Cancer ·Daniel W. Bowles, W W, Neil Senzer, Julie R. Brahmer, Alex A. Adjei, Michael A. Davies, Alexander J. Lazar, Alex Vo, Scott Peterson, Luke Walker, Diana F. Hausman, Charles M. Rudin, Antonio Jimeno	2013	53
4	A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non–Small-Cell Lung Cancer Journal of Thoracic Oncology ·Benjamin Levy, Alexander I. Spira, Daniel Becker, Tracey L. Evans, Ian D. Schnadig, D. Ross Camidge, Julie E. Bauman, Diana F. Hausman, Luke Walker, John Nemunaitis, Charles M. Rudin, Balázs Halmos, Daniel W. Bowles	2014	42
5	A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma Clinical Colorectal Cancer ·Daniel W. Bowles, Mark D. Kochenderfer, Allen Lee Cohn, Lucas Sidéris, Nghia Nguyen, Vivian Jean M. Cline-Burkhardt, Ian D. Schnadig, Minsig Choi, Lisle M. Nabell, Arvind Chaudhry, Robert L. Ruxer, Antonio Ucar, Diana F. Hausman, Luke Walker, Alexander I. Spira, Antonio Jimeno	2016	37
6	Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases Annals of Oncology ·Otto Metzger, José Pablo Leone, T. Li, Zhenying Tan‐Wasielewski, Lorenzo Trippa, William T. Barry, Jerry Younger, Elizabeth Lawler, Luke Walker, Rachel A. Freedman, Sara M. Tolaney, Ian E. Krop, Eric P. Winer, Nancy U. Lin	2020	35
7	Efficacy results of a phase 1b study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases. Journal of Clinical Oncology ·Virginia F. Borges, Cristiano Ferrario, Nathalie Aucoin, Carla I. Falkson, Qamar J. Khan, Ian E. Krop, Stephen Welch, Philippe L. Bédard, Alison Conlin, Jorge Chaves, Luke Walker, Erika Hamilton	2016	24
8	Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects The Journal of Clinical Pharmacology ·Ariel R. Topletz‐Erickson, Anthony Lee, JoAl Mayor, Evelyn Rustia, Layth I. Abdulrasool, Amanda L. Wise, Ben Dailey, Sharon DeChenne, Luke Walker, Stephen C. Alley, Christopher J. Endres	2020	22
9	A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck Investigational New Drugs ·Daniel W. Bowles, Neil Senzer, Diana F. Hausman, Scott Peterson, Alex Vo, Luke Walker, Roger B. Cohen, Antonio Jimeno	2014	19
10	Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers Clinical Pharmacokinetics ·Ariel R. Topletz‐Erickson, Anthony Lee, Evelyn Rustia, Hao Sun, JoAl Mayor, Layth I. Abdulrasool, Luke Walker, Christopher J. Endres	2022	11
11	Endovascular Doppler Guide Wire in Renal Arteries Investigative Radiology ·C Privat, A. Ravel, P. Chirossel, O. Borson, N Perez, P. Bourlet, Luke Walker, J. F. Viallet, L. Boyer	1999	9
12	Abstract OT-28-01: HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer Cancer Research ·Sara A. Hurvitz, Linda T. Vahdat, Nadia Harbeck, Antonio C. Wolff, Sara M. Tolaney, Sherene Loi, Norikazu Masuda, Joyce O’Shaughnessy, Cassie Dong, Luke Walker, Evelyn Rustia, Virginia F. Borges	2021	9
13	Abstract P4-21-01: Efficacy results of a phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases (mets) Cancer Research ·Erika Hamilton, V. Borges, Alison Conlin, Luke Walker, SL Moulder	2017	7
14	ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets). Journal of Clinical Oncology ·Cristiano Ferrario, Stephen Welch, Jorge Chaves, Luke Walker, Ian E. Krop, Erika Hamilton, Virginia F. Borges, Stacy L. Moulder	2015	6
15	PX-866 and docetaxel in patients with advanced solid tumors. Journal of Clinical Oncology ·Antonio Jimeno, Neil Senzer, Charles M. Rudin, Wen Wee, Balázs Halmos, Ian D. Schnadig, Benjamin Levy, Diana F. Hausman, Scott Peterson, Luke Walker	2012	6
16	698P Interim results from a phase I/II study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN) Annals of Oncology ·Noura J. Choudhury, Prantesh Jain, Afshin Dowlati, Jonathan R. Thompson, Melissa L. Johnson, Hirva Mamdani, Rachel E. Sanborn, Erin L. Schenk, Rahul Aggarwal, K. Nathan Sankar, Luke Walker, Banmeet S. Anand, Himisha Beltran	2023	5
17	The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment Clinical Pharmacokinetics ·Ariel R. Topletz‐Erickson, Anthony Lee, JoAl Mayor, Hao Sun, Layth I. Abdulrasool, Evelyn Rustia, Luke Walker, Christopher J. Endres	2022	5
18	SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress). Journal of Clinical Oncology ·Tom Stinchcombe, Bradley J. Monk, Alicia Okines, Paula R. Pohlmann, Evan Y. Yu, Tanios Bekaii‐Saab, Yoshiaki Nakamura, David M. O’Malley, Vicky Kang, Luke Walker, Martin Reck	2021	5
19	Abstract P4-14-19: ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets) Cancer Research ·RK Murthy, E.P. Hamilton, VF Borges, SL Moulder, Nathalie Aucoin, Stephen Welch, Felipe Javier Chaves, CI Falkson, Luke Walker, Cristiano Ferrario	2016	5
20	353TiP HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer Annals of Oncology ·Sara A. Hurvitz, Linda T. Vahdat, Nadia Harbeck, Antonio C. Wolff, SM Tolaney, Sherene Loi, Norikazu Masuda, Joyce O’Shaughnessy, Cassie Dong, Luke Walker, Evelyn Rustia, Virginia F. Borges	2020	4

About Luke Walker

Luke Walker is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Genetics and Small Animals, having authored 39 papers that have together received 489 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (21 papers), Cancer Treatment and Pharmacology (17 papers), Advanced Breast Cancer Therapies (12 papers), Brain Metastases and Treatment (8 papers), Lung Cancer Treatments and Mutations (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). The work is most often cited by research in Otorhinolaryngology (56 citations), Oncology (272 citations), Genetics (90 citations), Pulmonary and Respiratory Medicine (255 citations) and Molecular Biology (253 citations). Luke Walker has collaborated with scholars based in United States, Japan and Germany. Frequent co-authors include Diana F. Hausman, Antonio Jimeno, Alexander I. Spira, Daniel W. Bowles, Charles M. Rudin, Keisuke Shirai, Ian D. Schnadig, Mark D. Kochenderfer, Minsig Choi and Benjamin Levy. Their work appears in journals such as Annals of Oncology, Cancer Research, Journal of Clinical Oncology, Clinical Pharmacokinetics and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact